215 related articles for article (PubMed ID: 26270186)
1. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
Lo JA; Fisher DE; Flaherty KT
JAMA Oncol; 2015 Dec; 1(9):1340-1. PubMed ID: 26270186
[No Abstract] [Full Text] [Related]
2. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
Sanlorenzo M; Vujic I; Daud A; Algazi A; Gubens M; Luna SA; Lin K; Quaglino P; Rappersberger K; Ortiz-Urda S
JAMA Dermatol; 2015 Nov; 151(11):1206-1212. PubMed ID: 26222619
[TBL] [Abstract][Full Text] [Related]
3. Will cetuximab-induced follicular rash get worse with moisturizers containing liquid paraffinum?
Manganoni AM; Pavoni L; Calzavara-Pinton P
Jpn J Clin Oncol; 2014 Jun; 44(6):607-8. PubMed ID: 24755543
[No Abstract] [Full Text] [Related]
4. [Skin toxicity of monoclonal antibodies].
Cignola S; Campagna S; Gonella S
Assist Inferm Ric; 2017; 36(4):214-221. PubMed ID: 29200214
[No Abstract] [Full Text] [Related]
5. [Generalized pruritic eruption during terbinafine treatment].
Amouri M; El Euch D; El Ouni B; Daoued O; Ouselati MH; Ferjani M; Dhahri AB
Presse Med; 2008 Dec; 37(12):1836-40. PubMed ID: 18656325
[No Abstract] [Full Text] [Related]
6. Spironolactone-associated cutaneous effects: a case report and a review of the literature.
Gupta AK; Knowles SR; Shear NH
Dermatology; 1994; 189(4):402-5. PubMed ID: 7873830
[TBL] [Abstract][Full Text] [Related]
7. [Gottron-like papules induced by sunitinib].
Martorell-Calatayud A; Sanmartín O; Traves-Zapata V; Guillén C
Actas Dermosifiliogr; 2011 Jun; 102(5):385-7. PubMed ID: 21481331
[No Abstract] [Full Text] [Related]
8. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
[No Abstract] [Full Text] [Related]
9. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph K; Pongcharoen P; Vachiramon V
Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
[TBL] [Abstract][Full Text] [Related]
10. Skin toxicities of targeted therapies.
Segaert S; Chiritescu G; Lemmens L; Dumon K; Van Cutsem E; Tejpar S
Eur J Cancer; 2009 Sep; 45 Suppl 1():295-308. PubMed ID: 19775626
[No Abstract] [Full Text] [Related]
11. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation.
Bavbek S; Ataman Ş; Bankova L; Castells M
Allergol Immunopathol (Madr); 2013; 41(3):204-6. PubMed ID: 23063342
[No Abstract] [Full Text] [Related]
12. [Management of the cutaneous side effects of chemotherapies and targeted therapies].
Delyon J; Gerard M; Nicodeme M; Fromantin I; Loirat D
Soins; 2015 Jun; (796):17-24. PubMed ID: 26146316
[TBL] [Abstract][Full Text] [Related]
13. Risk of cumulative toxicity after complete melanoma response with pembrolizumab.
Hsieh AH; Faithfull S; Brown MP
BMJ Case Rep; 2017 Feb; 2017():. PubMed ID: 28148549
[TBL] [Abstract][Full Text] [Related]
14. Desensitization to chemotherapeutic agents.
Lieberman P; Castells M
J Allergy Clin Immunol Pract; 2014; 2(1):116-7. PubMed ID: 24565784
[No Abstract] [Full Text] [Related]
15. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
Oskan F; Belka C; Manapov F
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919
[No Abstract] [Full Text] [Related]
16. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
17. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
18. Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab.
Santos-Juanes J; Munguía Calzada P; Álvarez Fernández C
Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):410-411. PubMed ID: 30366590
[No Abstract] [Full Text] [Related]
19. Psoriasis-like Eruption triggered by Dupilumab Therapy.
Russo F; Provvidenziale L; Bruzziches F; Fiorani D; Santi F; Lamberti A; Lazzeri L; Flori ML; Rubegni P
Dermatitis; 2021 Nov-Dec 01; 32(6):e147-e148. PubMed ID: 34310097
[No Abstract] [Full Text] [Related]
20. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
Freites-Martinez A; Kwong BY; Rieger KE; Coit DG; Colevas AD; Lacouture ME
JAMA Dermatol; 2017 Jul; 153(7):694-697. PubMed ID: 28467522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
